Development of an enzymatic glucose biosensor for applications in wearable sweat-based sensing

The recent development and commercial availability of wearable devices like the FITBITî and Apple Watchî reflect an increasing consumer interest in actively monitoring health parameters. Though wearable devices are beginning to emerge in a variety of fields and applications, there is particular interest in the development of wearable monitors for continuously sensing blood glucose levels. Diabetes currently affects nearly 10% of the American population, a number that is expected to rise in the near future, prompting increased interest in noninvasive methods of monitoring glucose levels. This interest in noninvasive monitoring and the recent advent of continuous monitoring products like the FITBITî are coupled together in the concept of wearable glucose sensors that utilize sweat glucose concentration levels as a means to monitor blood glucose concentration. This work centers on sweat-based glucose biosensors with applications in continuous monitoring for diabetes patients. It includes an overview of glucose biosensors and an introduction to electrochemistry (Chapter 1) and an investigation into the effectiveness of electrodeposited platinum nanoparticles as a transduction element in electrochemical glucose biosensor (Chapter 2). A large part of this thesis (Chapter 3) is devoted to the development of an entirely inkjet printable working electrode for applications in wearable sensing. The developed electrode was fabricated entirely through inkjet printing using a commercially available Fujifilm Dimatix Materials Printer and characterization tests show that the sensor performs similarly to sensors fabricated using more costly and time-intensive clean room methods. The sensor consists of a conductive graphene underlayer, an insulative lacquer coating which serves to maintain constant electrode surface area, a transduction layer of platinum-decorated carbon nanotubes, a detection layer of glucose oxidase and stabilizing protein bovine serum albumin, and finally, a cross-linking layer of glutaraldehyde. When operating in phosphate buffer solution the sensor demonstrates a linear sensing range of 10 õM to 2.51 mM glucose, which is within the range of sweat glucose concentrations, a response time of 18 seconds, average sensitivity of 18.09 õA mM-1 cm-2, and a theoretical detection limit of 3.79 õM glucose

Platinum Nanoparticle Decorated SiO2 Microfibers as Catalysts for Micro Unmanned Underwater Vehicle Propulsion

Micro unmanned underwater vehicles (UUVs) need to house propulsion mechanisms that are small in size but sufficiently powerful to deliver on-demand acceleration for tight radius turns, burst-driven docking maneuvers, and low-speed course corrections. Recently, small-scale hydrogen peroxide (H2O2) propulsion mechanisms have shown great promise in delivering pulsatile thrust for such acceleration needs. However, the need for robust, high surface area nanocatalysts that can be manufactured on a large scale for integration into micro UUV reaction chambers is still needed. In this report, a thermal/electrical insulator, silicon oxide (SiO2) microfibers, is used as a support for platinum nanoparticle (PtNP) catalysts. The mercapto-silanization of the SiO2 microfibers enables strong covalent attachment with PtNPs, and the resultant PtNP–SiO2 fibers act as a robust, high surface area catalyst for H2O2 decomposition. The PtNP–SiO2 catalysts are fitted inside a micro UUV reaction chamber for vehicular propulsion; the catalysts can propel a micro UUV for 5.9 m at a velocity of 1.18 m/s with 50 mL of 50% (w/w) H2O2. The concomitance of facile fabrication, economic and scalable processing, and high performance—including a reduction in H2O2 decomposition activation energy of 40–50% over conventional material catalysts—paves the way for using these nanostructured microfibers in modern, small-scale underwater vehicle propulsion systems

Platinum Nanoparticle Decorated SiO 2 Microfibers as Catalysts for Micro Unmanned Underwater Vehicle Propulsion

Micro unmanned underwater vehicles (UUVs) need to house propulsion mechanisms that are small in size but sufficiently powerful to deliver on-demand acceleration for tight radius turns, burst-driven docking maneuvers, and low-speed course corrections. Recently, small-scale hydrogen peroxide (H2O2) propulsion mechanisms have shown great promise in delivering pulsatile thrust for such acceleration needs. However, the need for robust, high surface area nanocatalysts that can be manufactured on a large scale for integration into micro UUV reaction chambers is still needed. In this report a thermal/electrical insulator, silicon oxide (SiO2) microfibers, are used as a support for platinum nanoparticle (PtNP) catalysts. The mercapto-silanization of the SiO2 microfibers enables strong covalent attachment with PtNPs and the resultant PtNP-SiO2 fibers act as a robust, high surface area catalyst for H2O2 decomposition. The PtNP-SiO2 catalysts are fitted inside a micro UUV reaction chamber for vehicular propulsion; the catalysts can propel a micro UUV for 5.9 meters at a velocity of 1.18 m/s with 50 mL of 50% (w/w) H2O2.The concomitance of facile fabrication, economic and scalable processing, and high performance —including a reduction in H2O2 decomposition activation energy of 40-50% over conventional material catalysts—paves the way for using these nanostructured microfibers in modern, small-scale underwater vehicle propulsion systems

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Platinum Nanoparticle Decorated SiO2 Microfibers as Catalysts for Micro Unmanned Underwater Vehicle Propulsion

Micro unmanned underwater vehicles (UUVs) need to house propulsion mechanisms that are small in size but sufficiently powerful to deliver on-demand acceleration for tight radius turns, burst-driven docking maneuvers, and low-speed course corrections. Recently, small-scale hydrogen peroxide (H2O2) propulsion mechanisms have shown great promise in delivering pulsatile thrust for such acceleration needs. However, the need for robust, high surface area nanocatalysts that can be manufactured on a large scale for integration into micro UUV reaction chambers is still needed. In this report, a thermal/electrical insulator, silicon oxide (SiO2) microfibers, is used as a support for platinum nanoparticle (PtNP) catalysts. The mercapto-silanization of the SiO2 microfibers enables strong covalent attachment with PtNPs, and the resultant PtNP–SiO2 fibers act as a robust, high surface area catalyst for H2O2 decomposition. The PtNP–SiO2 catalysts are fitted inside a micro UUV reaction chamber for vehicular propulsion; the catalysts can propel a micro UUV for 5.9 m at a velocity of 1.18 m/s with 50 mL of 50% (w/w) H2O2. The concomitance of facile fabrication, economic and scalable processing, and high performance—including a reduction in H2O2 decomposition activation energy of 40–50% over conventional material catalysts—paves the way for using these nanostructured microfibers in modern, small-scale underwater vehicle propulsion systems.Reprinted with permission from ACS Applied Materials & Interfaces 8 (2016): 30941, doi:10.1021/acsami.6b10047.</p

Platinum Nanoparticle Decorated SiO2 Microfibers as Catalysts for Micro Unmanned Underwater Vehicle Propulsion

Micro unmanned underwater vehicles (UUVs) need to house propulsion mechanisms that are small in size but sufficiently powerful to deliver on-demand acceleration for tight radius turns, burst-driven docking maneuvers, and low-speed course corrections. Recently, small-scale hydrogen peroxide (H2O2) propulsion mechanisms have shown great promise in delivering pulsatile thrust for such acceleration needs. However, the need for robust, high surface area nanocatalysts that can be manufactured on a large scale for integration into micro UUV reaction chambers is still needed. In this report, a thermal/electrical insulator, silicon oxide (SiO2) microfibers, is used as a support for platinum nanoparticle (PtNP) catalysts. The mercapto-silanization of the SiO2 microfibers enables strong covalent attachment with PtNPs, and the resultant PtNP–SiO2 fibers act as a robust, high surface area catalyst for H2O2 decomposition. The PtNP–SiO2 catalysts are fitted inside a micro UUV reaction chamber for vehicular propulsion; the catalysts can propel a micro UUV for 5.9 m at a velocity of 1.18 m/s with 50 mL of 50% (w/w) H2O2. The concomitance of facile fabrication, economic and scalable processing, and high performance—including a reduction in H2O2 decomposition activation energy of 40–50% over conventional material catalysts—paves the way for using these nanostructured microfibers in modern, small-scale underwater vehicle propulsion systems.This article is published as Chen, Bolin, Nathaniel T. Garland, Jason Geder, Marius Pruessner, Eric Mootz, Allison Cargill, Anne Leners et al. "Platinum Nanoparticle Decorated SiO2 Microfibers as Catalysts for Micro Unmanned Underwater Vehicle Propulsion." ACS Applied Materials & Interfaces 8, no. 45 (2016): 30941-30947. DOI:10.1021/acsami.6b10047.</p

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div